Characteristics of the cohort with corresponding odds ratios (OR) and their 95% CI
| . | No GCA . | GCA . | OR . | 95% CI . |
|---|---|---|---|---|
| . | n (%) . | n (%) . | . | . |
| N | 194 | 132 | ||
| Age* | 66.7 (11.3) | 73.4 (9.7) | 1.06 | (1.04, 1.09) |
| Sex (female) | 139 (71.6) | 88 (67.7) | 0.83 | (0.51, 1.34) |
| Headache | 168 (87.5) | 111 (85.4) | 0.83 | (0.44, 1.60) |
| Scalp tenderness | 84 (43.8) | 60 (46.2) | 1.1 | (0.70, 1.72) |
| Temporal artery tenderness | 65 (33.5) | 50 (38.8) | 1.26 | (0.79, 2.00 |
| Jaw claudication | 37 (19.2) | 46 (35.4) | 2.29 | (1.38, 3.81) |
| Vision loss | 18 (9.4) | 32 (24.6) | 3.16 | (1.68, 5.91) |
| Other vision changes | 86 (45.3) | 61 (47.7) | 1.1 | (0.70, 1.73) |
| Constitutional symptoms | 43 (22.6) | 37 (29.1) | 1.41 | (0.84, 2.35) |
| Weight loss | 15 (7.8) | 18 (13.8) | 1.9 | (0.92, 3.92) |
| CRP (mg/dL)** | 4.7 (1.5–12.8) | 19.8 (5.5–50.7) | 1.02 | (1.01, 1.03) |
| ESR (mm/h)** | 20 (8–45) | 42 (21–70) | 1.02 | (1.01, 1.03) |
| Abnormal TA-MRA | 16 (8.4) | 77 (64.7) | 19.82 | (10.5, 37.41) |
| Underwent TAB | 105 (54.1) | 113 (86.9) | 5.63 | (3.15, 10.09) |
| TAB positivity | 0 0 | 44 (33.8) | – | – |
| Satisfies ACR 1990 criteria | 66 (34.0) | 71 (54.6) | 2.33 | (1.48, 3.68) |
| . | No GCA . | GCA . | OR . | 95% CI . |
|---|---|---|---|---|
| . | n (%) . | n (%) . | . | . |
| N | 194 | 132 | ||
| Age* | 66.7 (11.3) | 73.4 (9.7) | 1.06 | (1.04, 1.09) |
| Sex (female) | 139 (71.6) | 88 (67.7) | 0.83 | (0.51, 1.34) |
| Headache | 168 (87.5) | 111 (85.4) | 0.83 | (0.44, 1.60) |
| Scalp tenderness | 84 (43.8) | 60 (46.2) | 1.1 | (0.70, 1.72) |
| Temporal artery tenderness | 65 (33.5) | 50 (38.8) | 1.26 | (0.79, 2.00 |
| Jaw claudication | 37 (19.2) | 46 (35.4) | 2.29 | (1.38, 3.81) |
| Vision loss | 18 (9.4) | 32 (24.6) | 3.16 | (1.68, 5.91) |
| Other vision changes | 86 (45.3) | 61 (47.7) | 1.1 | (0.70, 1.73) |
| Constitutional symptoms | 43 (22.6) | 37 (29.1) | 1.41 | (0.84, 2.35) |
| Weight loss | 15 (7.8) | 18 (13.8) | 1.9 | (0.92, 3.92) |
| CRP (mg/dL)** | 4.7 (1.5–12.8) | 19.8 (5.5–50.7) | 1.02 | (1.01, 1.03) |
| ESR (mm/h)** | 20 (8–45) | 42 (21–70) | 1.02 | (1.01, 1.03) |
| Abnormal TA-MRA | 16 (8.4) | 77 (64.7) | 19.82 | (10.5, 37.41) |
| Underwent TAB | 105 (54.1) | 113 (86.9) | 5.63 | (3.15, 10.09) |
| TAB positivity | 0 0 | 44 (33.8) | – | – |
| Satisfies ACR 1990 criteria | 66 (34.0) | 71 (54.6) | 2.33 | (1.48, 3.68) |
*Mean (s.d.); **median and interquartile range. TAB: temporal artery biopsy.
Characteristics of the cohort with corresponding odds ratios (OR) and their 95% CI
| . | No GCA . | GCA . | OR . | 95% CI . |
|---|---|---|---|---|
| . | n (%) . | n (%) . | . | . |
| N | 194 | 132 | ||
| Age* | 66.7 (11.3) | 73.4 (9.7) | 1.06 | (1.04, 1.09) |
| Sex (female) | 139 (71.6) | 88 (67.7) | 0.83 | (0.51, 1.34) |
| Headache | 168 (87.5) | 111 (85.4) | 0.83 | (0.44, 1.60) |
| Scalp tenderness | 84 (43.8) | 60 (46.2) | 1.1 | (0.70, 1.72) |
| Temporal artery tenderness | 65 (33.5) | 50 (38.8) | 1.26 | (0.79, 2.00 |
| Jaw claudication | 37 (19.2) | 46 (35.4) | 2.29 | (1.38, 3.81) |
| Vision loss | 18 (9.4) | 32 (24.6) | 3.16 | (1.68, 5.91) |
| Other vision changes | 86 (45.3) | 61 (47.7) | 1.1 | (0.70, 1.73) |
| Constitutional symptoms | 43 (22.6) | 37 (29.1) | 1.41 | (0.84, 2.35) |
| Weight loss | 15 (7.8) | 18 (13.8) | 1.9 | (0.92, 3.92) |
| CRP (mg/dL)** | 4.7 (1.5–12.8) | 19.8 (5.5–50.7) | 1.02 | (1.01, 1.03) |
| ESR (mm/h)** | 20 (8–45) | 42 (21–70) | 1.02 | (1.01, 1.03) |
| Abnormal TA-MRA | 16 (8.4) | 77 (64.7) | 19.82 | (10.5, 37.41) |
| Underwent TAB | 105 (54.1) | 113 (86.9) | 5.63 | (3.15, 10.09) |
| TAB positivity | 0 0 | 44 (33.8) | – | – |
| Satisfies ACR 1990 criteria | 66 (34.0) | 71 (54.6) | 2.33 | (1.48, 3.68) |
| . | No GCA . | GCA . | OR . | 95% CI . |
|---|---|---|---|---|
| . | n (%) . | n (%) . | . | . |
| N | 194 | 132 | ||
| Age* | 66.7 (11.3) | 73.4 (9.7) | 1.06 | (1.04, 1.09) |
| Sex (female) | 139 (71.6) | 88 (67.7) | 0.83 | (0.51, 1.34) |
| Headache | 168 (87.5) | 111 (85.4) | 0.83 | (0.44, 1.60) |
| Scalp tenderness | 84 (43.8) | 60 (46.2) | 1.1 | (0.70, 1.72) |
| Temporal artery tenderness | 65 (33.5) | 50 (38.8) | 1.26 | (0.79, 2.00 |
| Jaw claudication | 37 (19.2) | 46 (35.4) | 2.29 | (1.38, 3.81) |
| Vision loss | 18 (9.4) | 32 (24.6) | 3.16 | (1.68, 5.91) |
| Other vision changes | 86 (45.3) | 61 (47.7) | 1.1 | (0.70, 1.73) |
| Constitutional symptoms | 43 (22.6) | 37 (29.1) | 1.41 | (0.84, 2.35) |
| Weight loss | 15 (7.8) | 18 (13.8) | 1.9 | (0.92, 3.92) |
| CRP (mg/dL)** | 4.7 (1.5–12.8) | 19.8 (5.5–50.7) | 1.02 | (1.01, 1.03) |
| ESR (mm/h)** | 20 (8–45) | 42 (21–70) | 1.02 | (1.01, 1.03) |
| Abnormal TA-MRA | 16 (8.4) | 77 (64.7) | 19.82 | (10.5, 37.41) |
| Underwent TAB | 105 (54.1) | 113 (86.9) | 5.63 | (3.15, 10.09) |
| TAB positivity | 0 0 | 44 (33.8) | – | – |
| Satisfies ACR 1990 criteria | 66 (34.0) | 71 (54.6) | 2.33 | (1.48, 3.68) |
*Mean (s.d.); **median and interquartile range. TAB: temporal artery biopsy.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
